Third Life Capital Healthcare Investment Summit Concludes with 900+ Matchmaking Sessions in 29 Hours
VCBeat (WeChat ID: vcbeat) has learned that the 3rd VCBeat Investment and Financing Summit, co-hosted by Life Capital and JLABS (Johnson & Johnson), officially opened with great fanfare on the afternoon of November 21 at the Cordis Shanghai Hongqiao Hotel, following more than two months of preparation.
Building on previous editions, this year’s conference has tripled in scale, with the duration extended to two days. It comprises three parallel sessions: Medical Devices, Smart Healthcare and Health Insurance, and Innovative Drugs.
Each conference is closed to the public, attended exclusively by 50 founders and 50 investors from the respective fields. Every founder undergoes rigorous vetting by an expert team, and each investor must be a fund partner or a senior investor with expertise in the relevant sector.
At the opening of the conference, Li Hao, CEO of Life Capital, delivered the inaugural address. He stated, “Each year, the Life Capital team engages with over a thousand healthcare startups, spanning various sectors including innovative drugs, medical devices, smart healthcare, and health insurance. Based on our communications and collaborations this year, the overall market funding environment remains tight. However, the more challenging the market conditions, the more we feel compelled to take action for the industry during this winter period. Therefore, we have tripled the scale of the Investment and Financing Summit, with the aim of providing more companies with opportunities to engage with investors.”
“Furthermore, to better serve the new generation of healthcare companies and fulfill its mission of empowering leaders in the health industry, Life Capital will no longer be content with positioning itself solely as a financial advisor. Instead, in collaboration with resource partners such as Johnson & Johnson JLABS and third-party service providers, it will provide comprehensive services ranging from private equity financing to mergers and acquisitions and business collaborations, thereby becoming a true long-term strategic partner for enterprises.”
Notably, the Innovative Drug Branch Meeting also received strong support from its co-organizer, the New Drug Founders Club. Mr. Zhao Qun, Partner at Yuanhe Origin and Deputy Secretary-General of the New Drug Founders Club, delivered an insightful speech on the current financing landscape at the opening of the conference.
Furthermore, as a pilot for VBInsight’s comprehensive strategic partnership services, the Innovative Drug Branch has pioneered the establishment of consultation booths for leading CROs, securities firms, and law firms. This enables founders to secure end-to-end resource matchmaking support within a single conference.
Subsequently, on the afternoon of the 21st and throughout the 22nd, the summit held three parallel sessions focused on medical devices, smart healthcare and health insurance, and innovative drugs. In each session, 50 founders and 50 investors engaged in six rounds of one-on-one meetings, creating a highly vibrant atmosphere.
In just over a day, enterprises and investors completed more than 900 one-on-one meetings. This efficient and precise matchmaking approach received widespread acclaim from attendees.
“The recognition of our team by founders and investors is the badge we are most proud of. Life Capital will remain true to its original aspiration, working hand in hand with all colleagues to contribute to the vigorous development of China’s healthcare sector and jointly fulfill our mission of ‘Empowering Leaders in the Health Industry,’” concluded Li Hao, CEO of Life Capital.
About Life Capital
Life Capital is China’s leading financial services institution focused on the life sciences and healthcare sectors. Its business portfolio encompasses healthcare investment banking and healthcare funds, dedicated to cultivating the future industry leaders in the health sector.
The team comprises professionals from renowned investment banks, academic institutions, and healthcare companies, with decades of accumulated expertise in the healthcare and investment and financing sectors.
Over the past three years, the team has completed dozens of financing and M&A transactions in the healthcare industry, with a cumulative value reaching several billion RMB. These deals span various healthcare subsectors, including new drug R&D, medical devices, diagnostics, healthcare services, and smart healthcare. Notable success stories include Lanyu Biotechnology, Sinocelltech, Rongzhi Biotechnology, Qiyu Biotechnology, Jiahui Health, ImmuneOnco, Antengene, Lainuo Medical, Beden Medical, Taimei Technology, and Airdoc.
Related Reading: